XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
A hybrid system — one where electronic records are supplemented by paper records, or where GMP activities are recorded in both an electronic system and a paper logbook — is not a compliance solution.
View details →
Specifications for a lipid nanoparticle drug product are not borrowed from liposome specifications, small molecule specifications, or monoclonal antibody specifications. They are built from first principles — from the CQA risk assessment, the manufacturing
View details →
Data integrity enforcement in pharmaceutical manufacturing has focused overwhelmingly on analytical chemistry laboratories — HPLC systems, balances, LIMS — while the microbiological laboratory, with its unique combination of subjective result interpretation, paper-based colony counting,
View details → Lipid nanoparticles are thermodynamically metastable systems. They do not exist at equilibrium — they are kinetically trapped structures whose continued integrity depends on an ongoing balance of steric stabilization, electrostatic repulsion, and lipid bilayer
View details → FDA's rewritten Preapproval Inspection compliance program — Compliance Program 7346.832, revised June 29, 2026 and effective today, August 10, 2026 — replaces the old checklist approach to PAIs with a risk-based model built around
View details →
The FDA's 2011 Process Validation guidance applies to LNP manufacturing. What requires careful thinking is how the three-stage framework maps onto a process where the critical transformation happens in a subsecond mixing event, where
View details → ICH Q2(R2) reached ICH Step 4 in 2023 and was issued as final FDA guidance in March 2024 and introduced changes to analytical method validation that go beyond terminology updates — the revised guideline
View details → "The regulatory framework for lipid nanoparticle drug products is still being built in real time. Understanding which regulatory framework applies to your LNP program — and how to navigate the jurisdiction question within FDA
View details →
The most common reason FDA issues a Complete Response Letter for CMC deficiencies related to specifications is not that the acceptance criteria are wrong — it is that the submission does not contain the
View details → PEG-lipid is a structural component of every approved LNP drug product. Without it, the LNP as a systemic delivery vehicle does not function. And yet PEG-lipid brings with it a pharmacological liability that has
View details → A post-approval manufacturing change that required a Prior Approval Supplement but was submitted as a Changes Being Effected in 30 Days notification is not a submission strategy — it is a regulatory violation that
View details → Patisiran (Onpattro) was approved by FDA on August 10, 2018 — the first RNA interference drug product to receive regulatory approval anywhere in the world, delivered in an LNP formulation using DLin-MC3-DMA as the
View details → The Annual Product Review — or Product Quality Review as EU GMP calls it — is one of the most universally produced and most universally underutilized documents in pharmaceutical manufacturing, and the companies that
View details →
The COVID-19 mRNA vaccine programs created a widespread assumption that the CMC framework developed for mRNA vaccines applies directly to mRNA therapeutics. It does not — not entirely — and understanding the differences is
View details → When FDA issues a 483 observation for inadequate control of materials, the citation almost always traces back to a supplier qualification program that checked a box rather than built a quality system — a
View details → The helper lipid is the least-discussed component of the 4-component ionizable LNP formulation, and that silence is a CMC problem. When a reviewer opens your 3.2.P.2 pharmaceutical development section and asks why DSPC was
View details → Only about 8 to 12 percent of FDA 483 observations result in a Warning Letter — but the companies that receive Warning Letters almost always had the opportunity to prevent them, because the patterns
View details → Three FDA-approved LNP drug products — Onpattro, Comirnaty, and Spikevax — have publicly documented ionizable lipid drug substance packages with complete 3.2.S sections, ICH Q7 GMP synthesis histories, and impurity profiles qualified under ICH
View details →